Pharmacotherapy of Pervasive Developmental Disorders in Children and Adolescents

@article{Masi2004PharmacotherapyOP,
  title={Pharmacotherapy of Pervasive Developmental Disorders in Children and Adolescents},
  author={Gabriele Masi},
  journal={CNS Drugs},
  year={2004},
  volume={18},
  pages={1031-1052}
}
  • G. Masi
  • Published 2004
  • Medicine
  • CNS Drugs
Pervasive developmental disorders (PDDs) are severe psychiatric disorders characterised by impaired social interaction, reduced verbal and nonverbal communication, and restricted and stereotyped patterns of interest and behaviour, with onset in the first 3 years of life. As part of a multimodal approach that includes educational and behavioural interventions, appropriate use of pharmacotherapy in patients with PDDs can improve some symptoms and behaviours and increase the patient’s response to… Expand
Aripiprazole Monotherapy in Children and Young Adolescents with Pervasive Developmental Disorders
TLDR
In these severely impaired children with PDDs, aripiprazole monotherapy was associated with a significant improvement in maladaptive behaviours in one-third of patients. Expand
Use of Atypical Antipsychotics in the Treatment of Autistic Disorder
TLDR
Atypical antipsychotics represent a treatment option for symptoms associated with autistic disorder, however, these drugs do not affect the core symptoms of autistic disorder and are associated with potentially significant adverse effects. Expand
Pharmacotherapy of bipolar disorder in children and adolescents
TLDR
Although several evidence-based medications are now available for the treatment of BPD in younger populations, additional studies to evaluate the short- and long-term efficacy and potential for adverse events of these and other medications are needed. Expand
Prepubertal bipolar disorder: available pharmacological treatment options
  • G. Masi
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2005
TLDR
This review focuses on the empirical evidence for pharmacotherapy in paediatric bipolar disorder and the prophylaxis of intercritical phases and the management of specific challenging conditions, such as bipolar depression and attention deficit hyperactivity disorder, with bipolar comorbidity. Expand
Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study.
TLDR
Assessment of the effects of ongoing methylphenidate (MPH) on ADHD-related and autistic symptoms in Pervasive Developmental Disorders in children who did not present any adverse effects to an initial acute dose administered at the clinic concluded that Administering a single MPH test dose may be useful in identifying children with PDD who may benefit from prolonged therapy. Expand
Pharmacotherapy of adult attention deficit/hyperactivity disorder: review of evidence-based practices and future directions
TLDR
The reviewed body of evidence strongly supports the use of pharmacotherapy as a first-line therapeutic option for the treatment of adults with ADHD. Expand
Glutamate-mediated neuroplasticity in an animal model of self-injurious behaviour
TLDR
It is suggested that repeated pemoline administration induces glutamate-mediated neuroplastic changes that lead to the eventual expression of SIB. Expand
Treatment of Severe Self-Injurious Behavior in Autism Spectrum Disorder by Neuromodulation.
TLDR
This review explores the expanding literature supporting the use of ECT for suppressing severe SIB associated with autism spectrum disorder and the possible development of alternate nonconvulsive focal forms of brain stimulation, which might replace frequent M-ECT or reduce how frequently a patient needs to receive it. Expand
Self-Injurious Behavior: II. Pharmacological and Integrated Treatments
This is the second of two chapters reviewing treatment of self-injurious behavior (SIB) in people with pervasive developmental disabilities (PDDs). The preceding chapter reviewed the generalExpand
Self-injury in autism as an alternate sign of catatonia: implications for electroconvulsive therapy.
TLDR
People with autism and other developmental disorders who develop severe self-injury (with or without concomitant tics) should be assessed for catatonia, and ECT should be considered as a treatment option. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 148 REFERENCES
Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up.
TLDR
Despite the small sample size, risperidone treatment appeared to be associated with significant improvements in ratings of angry affect and lability of affect and with a trend toward a reduction of mean hyperactivity scores, which suggests pharmacologic alternatives for treating behavioral symptoms in PDD may be a promising possibility. Expand
Risperidone in children with autism and serious behavioral problems.
TLDR
Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder and the benefit was maintained at six months. Expand
Venlafaxine in Children, Adolescents, and Young Adults With Autism Spectrum Disorders: An Open Retrospective Clinical Report
TLDR
Control treatment trials with venlafaxine are warranted in autism spectrum disorders after improvement was noted in repetitive behaviors and restricted interests, social deficits, communication and language function, inattention, and hyperactivity. Expand
A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders.
TLDR
The results of this case series suggest that citalopram has beneficial effects on some interfering behaviors associated with PDDs with few adverse effects, and controlled trials are warranted. Expand
Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation.
TLDR
The data indicate that risperidone is an effective and relatively safe drug for long term treatment of behavioral disruption in autistic children and adolescents. Expand
Clonidine Treatment of Hyperactive and Impulsive Children with Autistic Disorder
TLDR
Clonidine was modestly effective in the short-term treatment of irritability and hyperactivity in some children with autistic disorder. Expand
Open-Label Study of Olanzapine in Children with Pervasive Developmental Disorder
TLDR
Olanzapine was a relatively safe medication in children, its clinical relevance in children with pervasive developmental disorder may be limited, and three children showed extrapyramidal symptoms that disappeared after the dose was lowered. Expand
Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness.
TLDR
Risperidone shows promise as a treatment in autism, however, withdrawal dyskinesias were noted and the need for further drug treatment and the occurrence of withdrawal Dyskinesia were assessed. Expand
Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone.
TLDR
The background and rationale for the choice of risperidone as the first drug to be studied by the RUPP Autism Network is reviewed, and indirect clinical and preclinical evidence supports the use of ris peridone to treat impaired social behavior, interfering repetitive phenomena, and aggression. Expand
Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder.
TLDR
This open-label study suggests that short-term sertraline treatment may reduce the behavioral reactions seen in association with situational transitions or environmental changes in children with autistic disorder, though the beneficial effect may be only temporary in some children. Expand
...
1
2
3
4
5
...